RxDoctor Payments Data

Cynthia Williams, MD

Endocrinology, Diabetes & Metabolism · Torrance, CANPI 1265485049

Payments from drug & device makers

$1,062in general payments, 2019–2025

Across 37 payments — averaging $28.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$309
  • AbbVie$170
  • Radius Health, Inc.$123
  • Abbott$68
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$58
  • Takeda Pharmaceuticals U.S.A., Inc.$54
  • plus $280 from 11 others

What the payments were for

  • Food & beverage$99093%
  • Education$727%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,062 in reported general payments places this provider in the 45th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$419,841
Medicare patients
296
Services billed
6,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide165$222,466
OzempicSemaglutide165$171,955
Repatha SureclickEvolocumab175$153,257
EliquisApixaban119$115,069
JanuviaSitagliptin Phosphate50$58,970
FarxigaDapagliflozin Propanediol47$49,820
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$40,573
XifaxanRifaximin13$39,820
XareltoRivaroxaban18$28,938
TrulicityDulaglutide20$25,151
SynthroidLevothyroxine Sodium210$23,247
Repatha SyringeEvolocumab22$23,075
Praluent PenAlirocumab37$22,302
TrintellixVortioxetine Hydrobromide30$21,847
MyrbetriqMirabegron21$20,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$27$171,955165 claims
AstraZenecaFarxiga, Symbicort$20$54,16263 claims
AbbVieSynthroid, Linzess, Armour Thyroid$170$43,820248 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$23$39,82013 claims
Boehringer IngelheimJardiance, Synjardy$24$24,11224 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$54$21,84730 claims
Astellas Pharma US IncMyrbetriq$40$20,57621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →